The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).
 
Theodore S. Hong
Stock and Other Ownership Interests - PanTher Therapeutics
Consulting or Advisory Role - Boston Scientific; Merck; Novocure; Syndax; Synthetic Biologics
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); IntraOp (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
 
Beow Y. Yeap
No Relationships to Disclose
 
Nora K. Horick
Employment - Northwest Biotherapeutics (I)
Stock and Other Ownership Interests - Northwest Biotherapeutics (I)
Patents, Royalties, Other Intellectual Property - An immediate family member holds patents, has patents pending, and receives royalties from a technology relating to health or medicine. (I)
 
Jennifer Yon-Li Wo
Honoraria - PER
Research Funding - Genentech/Roche (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - Lynx Group
 
Colin D. Weekes
Honoraria - Bayer; Celgene; Lilly
Consulting or Advisory Role - Celgene; Ipsen; Merrimack
Research Funding - Actuate Therapeutics; AstraZeneca; Celgene; Dicephera Pharmaceuticals, Inc.; Genentech/Roche; Novartis
 
Jill N. Allen
No Relationships to Disclose
 
Motaz Qadan
No Relationships to Disclose
 
Paul Eliezer Oberstein
Consulting or Advisory Role - AstraZeneca; Delcath Systems; Merck; QED Therapeutics; Rubius Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Arcus Biosciences (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Rakesh K. Jain
Leadership - Tekla Capital Management; Tekla Capital Management; Tekla Capital Management; Tekla Capital Management
Stock and Other Ownership Interests - Accurius; Enlight Biosciences; SynDevRx
Consulting or Advisory Role - Cur Therapeutics; Ellipses Pharma; Innocoll Therapeutics; SPARC; SynDevRx
Research Funding - Boehringer Ingelheim
(OPTIONAL) Uncompensated Relationships - Twenty-eight-Seven
 
Lawrence Scott Blaszkowsky
Stock and Other Ownership Interests - Pfizer (I)
 
Brian M. Wolpin
Honoraria - Celgene; G1 Therapeutics; Mirati Therapeutics
Consulting or Advisory Role - BioLineRx; Celgene; G1 Therapeutics; Genentech; GRAIL; Mirati Therapeutics
Research Funding - Celgene; Lilly; Novartis; Revolution Medicines
 
Daniel A. Laheru
No Relationships to Disclose
 
Wells A. Messersmith
Honoraria - Research to Practice (Inst)
Consulting or Advisory Role - Criterium (Inst); Five Prime Therapeutics (Inst); Istari Oncology; QED Therapeutics; Zymeworks
Research Funding - ALX Oncology (Inst); Beigene (Inst); CanBas (Inst); D3 (Inst); Exelixis (Inst); FATE Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); RasCal (Inst)
 
Leilana Ly
No Relationships to Disclose
 
Lorraine C. Drapek
No Relationships to Disclose
 
David Tsai Ting
Leadership - PanTher Therapeutics
Stock and Other Ownership Interests - PanTher Therapeutics; ROME Therapeutics; TellBio
Consulting or Advisory Role - Ikena Oncology; NanoString Technologies; Pfizer; ROME Therapeutics; Tekla Capital Management
Research Funding - ACD Biotechne (Inst); PureTech (Inst); Ribon Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent License to PanTher Therapeutics (Inst); Patent License to TellBio Inc. (Inst); Patent licensed to Rome Therapeutics by my Institution. (Inst)
 
Richard A. Burkhart
No Relationships to Disclose
 
Carlos Fernandez-del Castillo
No Relationships to Disclose
 
Alec Kimmelman
Stock and Other Ownership Interests - Rafael Pharmaceuticals; Vescor Therapeutics
Consulting or Advisory Role - Abbvie; Deciphera; Vescor Therapeutics
Patents, Royalties, Other Intellectual Property - inventor on patents pertaining to Kras regulated metabolic pathways, redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach and the autophagic control of iron metabolism, and targeting alanine transport in pancreatic cancer; inventor on patents pertaining to Kras regulated metabolic pathways, redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach and the autophagic control of iron metabolism, and targeting alanine transport in pancreatic cancer
 
David P. Ryan
Stock and Other Ownership Interests - Acworth Pharmaceuticals; Bioimpact Capital; Cullinan Oncology; Exact Sciences; MPM Capital; Thrive Earlier Detection Corp
Honoraria - Research to Practice; UpToDate
Consulting or Advisory Role - Gritstone Bio; Innocrin Pharma; Maverick Therapeutics; MPM Capital; Oncorus; TCR2 Therapeutics; Twentyeight-Seven Therapeutics
Research Funding - Stand up to Cancer (Inst)
Patents, Royalties, Other Intellectual Property - Johns Hopkins University Press; McGraw Hill Chapter Royalties
Expert Testimony - Boehringer Ingelheim
Other Relationship - TCR2 Therapeutics